Abstract:Objective To evaluate the reliability, responsiveness, and validity of the Scale for the Assessment and Rating of Ataxia (SARA) in patients with Lysosomal Storage Disorders (LSDs) who present with neurological symptoms and quantify the threshold for a clinically meaningful change. Methods We analyzed data from three clinical trial cohorts (IB1001-201, IB1001-202, IB1001-301) of patients with Niemann-Pick disease type C (NPC) and GM2 Gangliosidoses (Tay-Sachs and Sandhoff disease) comprising 122 patients and 703 visits. Reproducibility was described as retest reliability between repeat baseline visits or baseline vs. post-treatment washout visits. Responsiveness was determined in relation to the Investigator, Caregiver, and Patient Clinical Global Impression of Improvement (CGI-I). The CGI-I data was also used to quantify a threshold for a clinically meaningful improvement on the SARA scale. Using a qualitative methods approach, patient/caregiver interviews from the IB1001-301 trial were further used to assess a threshold of meaningful change as well as the breadth of neurological signs and symptoms captured and evaluated by the SARA scale. Results The Inter-Class Correlation (ICC) was 0.95 or greater for all three trials, indicating a high internal consistency/reliability. The mean change in SARA between repeat baseline or post-treatment washout visit assessments in all trials was -0.05, SD 1.98, i.e. minimal, indicating no significant differences, learning effects or other systematic biases. For the CGI-I responses and change in SARA scores Area Under the Curve (AUC) values were 0.82, 0.71, and 0.77 for the Investigator, Caregiver, and Patient CGI-I respectively, indicating strong agreement. Further qualitative analyses of the patient/caregiver interviews demonstrated a 1-point or greater change on SARA to be a clinically meaningful improvement which is directly relevant to the patients' everyday functioning and quality of life. Changes captured by the SARA were also paralleled by improvement in a broad range of neurological signs and symptoms and beyond cerebellar ataxia. Conclusion Qualitative and quantitative data demonstrate the reliability and responsiveness of the SARA score as a valid measure of neurological signs and symptoms in LSDs. A 1-point change represents a clinically meaningful transition reflecting the gain or loss of complex function.

FARS‐ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change

Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients

Psychometric Validation of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) in Patients With Spinocerebellar Ataxia

Evaluating mFARS in pediatric Friedreich's ataxia: Insights from the FACHILD study

Content Validity of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Instrument in Spinocerebellar Ataxia

Item performance of the scale for the assessment and rating of ataxia in rare and ultra‐rare genetic ataxias

Cardiopulmonary exercise testing on adaptive equipment in children and adults with Friedreich ataxia

Digital Gait Outcomes for Autosomal Recessive Spastic Ataxia of Charlevoix‐Saguenay (ARSACS): Discriminative, Convergent, and Ecological Validity in a Multicenter Study (PROSPAX)

Accelerometer-based measures in Friedreich ataxia: a longitudinal study on real-life activity

A wearable motion capture suit and machine learning predict disease progression in Friedreich’s ataxia

Longitudinal Analysis of Natural History Progression of Rare and Ultra-Rare Cerebellar Ataxias Using Item Response Theory

Friedreich's Ataxia-Health Index: Development and Validation of a Novel Disease-Specific Patient-Reported Outcome Measure

Frontotemporal-spectrum disorders and functional independence in non-demented ALS patients

Standing Balance Conditions and Digital Sway Measures for Clinical Trials of Friedreich's Ataxia

Respiratory Function in Friedreich's Ataxia

Friedreich Ataxia Caregiver-Reported Health Index: Development of a Novel, Disease-Specific Caregiver-Reported Outcome Measure

Assessment of the Reliability, Responsiveness, and Meaningfulness of the Scale for the Assessment and Rating of Ataxia (SARA) for Lysosomal Storage Disorders

Exploring neuropsychiatric symptoms in Friedreich ataxia

Sensitivity of Advanced Magnetic Resonance Imaging to Progression over Six Months in Early Spinocerebellar Ataxia

Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported Outcomes

The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials